ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cancer"

  • Abstract Number: 2395 • 2017 ACR/ARHP Annual Meeting

    Recommendations on the Management of Rheumatoid Arthritis in Patients with Cancer: A Systematic Review of Clinical Practice Guidelines and Consensus Statements

    Maria A. Lopez-Olivo1, Ines Colmegna2, Aliza Matusevich1, Susan Ruyu Qi3, Natalia Zamora1, Robin Sharma1, Gregory Pratt4 and Maria Suarez-Almazor1, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 2Division of Rheumatology, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada, 3Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada, Montreal, QC, Canada, 4Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX

    Background/Purpose: To compare the recommendations of clinical practice guidelines (CPGs) and consensus statements (CSs) regarding the management of rheumatoid arthritis (RA) in patients with cancer.…
  • Abstract Number: 2735 • 2017 ACR/ARHP Annual Meeting

    Is There an Association between Adult IgA Vasculitis and Cancer?

    Jaka Ostrovrsnik1, Ziga Rotar1, Rok Jese1, Matija Tomšič1,2 and Alojzija Hočevar1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia

    Background/Purpose: An increased incidence rate of cancer has been reported in adult patients with IgA vasculitis (IgAV). These conclusions are mostly based on observations in…
  • Abstract Number: 2739 • 2017 ACR/ARHP Annual Meeting

    Onco-Hematological Malignancies in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials

    Lafarge Antoine1, Christian Pagnoux2, Xavier Puéchal3, Maxime Samson4, Mohamed Hamidou5, Alexandre Karras6, Thomas Quémeneur7, Matthieu Groh8, Luc Mouthon9, Loïc Guillevin for the French Vasculitis Study Group3 and Benjamin Terrier10, 1Medecine Interne, Hôpital Cochin, Paris, France, 2Mount Sinai Hospital, Toronto, ON, Canada, 3Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, 4Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 5Medecine Interne, CHU Hôtel Dieu, Nantes, France, 6nephrology, HEGP, Paris, France, 7Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, 8National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 9Université Paris Descartes Sorbonne Paris, Paris, France, 10Internal Medicine, Cochin University Hospital, Paris, France

    Background/Purpose: The use of long-term immunosuppressive agents in patients with systemic necrotizing vasculitides has dramatically improved the overall prognosis, but expose patients to potential severe…
  • Abstract Number: 2447 • 2016 ACR/ARHP Annual Meeting

    Does a History of Abnormal Pap Smear or Preceeding HPV Infection Affect Humoral Immune Response to Quadrivalent Human Papilloma Virus (qHPV) Vaccine in Women with Systemic Lupus Erythematosus (SLE)

    J. Patricia Dhar1,2, Lynnette Essenmacher3, Renee Dhar4, Ardella Magee5, Joel Ager6 and Robert Sokol7, 1Internal Medicine, Wayne State University School of Medicine, Detroit, MI, 2Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, 3Wayne State University School of Medicine, Detroit, MI, 4CMED medical student, Central Michigan University College of Medicine, Mt. Pleasant, MI, 5Clinical and Translational Research Center, Wayne State University, Detroit, MI, 6Family Medicine, Wayne State University School of Medicine, Detroit, MI, 7Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI

    Background/Purpose: Cervical neoplasia is increased in women with SLE. HPV types 16 & 18 account for 70% of cervical cancer. Natural HPV cervical infection generates…
  • Abstract Number: 2629 • 2016 ACR/ARHP Annual Meeting

    Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry

    Kaleb Michaud1,2, Sofia Pedro2, TA Simon3, Frederick Wolfe2 and Rebecca Schumacher2, 1University of Nebraska Medical Center, Omaha, NE, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Observational studies are critical in assessing medication safety and effectiveness in the real world. Nonrandom assignment can provide insight to how and when medications…
  • Abstract Number: 2990 • 2016 ACR/ARHP Annual Meeting

    Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort

    Sasha Bernatsky1, Murray Urowitz2, John Hanly3, Ann E. Clarke4, Caroline Gordon5, Juanita Romero-Diaz6, Graciela S. Alarcon7, Sang-Cheol Bae8, Michelle Petri9, Joan T. Merrill10, Daniel J Wallace11, Paul R. Fortin12, Dafna D. Gladman13, David A. Isenberg14, Anisur Rahman15, Susan Manzi16, Ola Nived17, Gunnar K. Sturfelt18, Christine Peschken19, Jorge Sánchez-Guerrero20, Guillermo Ruiz-Irastorza21, Cynthia Aranow22, Ronald F. van Vollenhoven23, Asad Zoma24, Kristján Steinsson25, M Khamashta26, Ellen M. Ginzler27, Anca Askanase28, Kenneth C. Kalunian29, Mary Anne Dooley30, S. Sam Lim31, Diane L. Kamen32, Søren Jacobsen33, Manuel Ramos-Casals34, Murat Inanc35, Jeremy Labrecque36, Jennifer LF Lee37 and Rosalind Ramsey-Goldman38, 1Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 2Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, 4Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 5NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 6Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, 7Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 8Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of, 9Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, 10Oklahoma Medical Research Foundation, Oklahoma City, OK, 11Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 12Université Laval, CHU de Québec, Québec, QC, Canada, 13Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 14Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 15Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, 16Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, 17Department of Rheumatology, University Hospital, Lund, Sweden, 18Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, 19Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, 20Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, 21Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, 22Feinstein Institute for Medical Research, Manhasset, NY, 23Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, 24Hairmyres Hospital, Scotland, United Kingdom, 25Rheumatology, Univ. Hospital, Reykjavik, Iceland, 26Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, 27Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, 28NYU, Seligman Centre for Advanced Therapeutics, New York, NY, 29Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, 30Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, 31Medicine, Emory University School of Medicine, Atlanta, GA, 32Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 33Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 34Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 35Internal Medicine, Istanbul University, Istanbul, Turkey, 36Clinical Epidemiology, McGill UHC/RVH, Montreal, QC, Canada, 37Clinical Epidemiology Rheum, McGill UHC/RVH, Montreal, QC, Canada, 38FSM, Northwestern University, Chicago, IL

    Background/Purpose:  Published studies of cancer risk in SLE to date have never focussed solely on clinically confirmed, incident patients. Prior studies thus may not reflect the cancer…
  • Abstract Number: 3067 • 2016 ACR/ARHP Annual Meeting

    Treatment Decisions Following Diagnosis of Cancer during TNFi Inhibitor Treatment in Patients with Rheumatoid Arthritis: Results from the BSRBR-RA

    Katie Druce1, Diederik Decock2, Kath Watson1, Deborah P.M. Symmons1 and Kimme L. Hyrich1, 1Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 2KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium

    Treatment Decisions Following Diagnosis of Cancer During TNFi inhibitor Treatment in Patients with Rheumatoid Arthritis: results from the BSRBR-RA Druce KL, De Cock D, Watson…
  • Abstract Number: 3080 • 2016 ACR/ARHP Annual Meeting

    Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg

    Laura Cappelli1, Anna Kristina Gutierrez2, Alan N. Baer2, Jemima Albayda3, Rebecca L. Manno2, Uzma Haque3, Ami A. Shah3, Evan Lipson4, Karen Bleich5, Julie Brahmer4, Patrick Forde4, Dung Le6, Jarushka Naidoo4 and Clifton Bingham III7, 1Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 5Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, 6Johns Hopkins University School of Medicine, Baltimore, MD, 7Johns Hopkins University, Baltimore, MD

    Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg   Background/Purpose:  Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed…
  • Abstract Number: 26 • 2016 ACR/ARHP Annual Meeting

    Rheumatoid Factor Positivity Increases All-Cause and Cancer Mortality Risk in Korean Healthy Examinees: A Kangbuk Samsung Health Study

    Joong Kyong Ahn1, Jiwon Hwang2, Hyemin Jeong3, Ji Young Chae4, Hyungjin Kim3, Hoon-Suk Cha3 and Eun-Mi Koh3, 1Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Department of Medicine, National Police Hospital, Seoul, Korea, The Republic of, 3Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 4Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of

    Background/Purpose:  Several studies have reported increased overall mortality in association with rheumatoid factor (RF) in RA. However, the clinical significance including health outcomes of RF…
  • Abstract Number: 330 • 2016 ACR/ARHP Annual Meeting

    Safety of Denosumab in Postmenopausal Osteoporosis and in Cancer and Bone Metastase Treatment: A Systematic Review and Meta-Analysis

    Marlène Aubailly1, Bernard Combe2, Cécile Gaujoux-Viala3, Cédric Lukas4, Jacques Morel5 and Hélène Che1, 1rheumatology, CHU Lapeyronie, University of Montpellier, France, 2Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 3CHU Nîmes, University of Montpellier, France, 4Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, 5Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France

    Background/Purpose: Denosumab is a RANK ligand antibody and the first biologic agent used for the treatment of post-menopausal osteoporosis (OP) and prevention of bone metastases…
  • Abstract Number: 855 • 2016 ACR/ARHP Annual Meeting

    The Relationship Between Systemic Sclerosis and Breast Cancer and the Effects on Treatment Outcome

    Pichaya O-charoen1, Katherine Glass2, William Messner3 and Soumya Chatterjee4, 1Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 2Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 4Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Breast cancer has been shown to be more prevalent in patients with systemic sclerosis (SSc) compared to that in the general population. A close…
  • Abstract Number: 2000 • 2016 ACR/ARHP Annual Meeting

    Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept

    Jacques-Eric Gottenberg1, Philippe Ravaud2, Thomas Bardin3, Alain Cantagrel4, Bernard Combe5, Maxime Dougados6, RENE MARC FLIPO7, Olivier Vittecoq8, Thierry Schaeverbeke9, Isabelle Pane10, Jean Sibilia11, Xavier Mariette12 and on behaf of all of the investigators of the AIR registry and of the French Society of Rheumatology , 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Epidemiology, Hotel Dieu, PARIS, France, 3Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 4Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, 5Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 6Rheumatology, Paris Descartes University, Paris, France, 7Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, 8INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, 9Rheumatology, CHU Bordeaux, Bordeaux, France, 10Epidemiology, Hotel Dieu, Paris, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France

    Background/Purpose: Patients with a history of cancer were excluded from pivotal clinical trials evaluating biologics. Therefore, only registries can inform us on the incidence of…
  • Abstract Number: 2304 • 2016 ACR/ARHP Annual Meeting

    Decreased Occurrence of Colon Cancer Among Gout Patients: Assessment By Physician Diagnosis and Colonoscopy

    Anastasia Slobodnick1,2, Svetlana Krasnokutsky Samuels3, Aaron Lehmann4, Robert Keenan5, Fritz Francois6 and Michael H. Pillinger3,7, 1Medicine/Rheumatology, NYU School of Medicine, New York, NY, 2Medicine/Rheumatology, VA New York Harbor Health Care System, NY Campus, New York, NY, 3VA New York Harbor Health Care System, New York, NY, 4Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, 5Division of Rheumatology, Duke University, Durham, NC, 6Medicine/Gastroenterology, NYU School of Medicine, New York, NY, 7NYU School of Medicine, New York, NY

    Background/Purpose: The relationship between gout and cancer remains unclear. Whereas some studies have reported possible anti-cancer benefits of uric acid and monosodium urate crystals, others…
  • Abstract Number: 2314 • 2016 ACR/ARHP Annual Meeting

    Anti-Mi2 Dermatomyositis Revisited: Pure DM Phenotype with Muscle Fiber Necrosis and High Risk of Malignancy

    Océane Landon-Cardinal1, Grégoire Monseau2, Yoland Schoindre3, Aude Rigolet1, Nicolas Champtiaux1, Baptiste Hervier1, Agathe Masseau4, Eric Hachulla5, Thomas Papo6, Benjamin Terrier7, Alain Meyer8, Jean-Emmanuel Kahn3, François Maurier9, Francis Gaches10, Emmanuelle Salort-Campana11, Thierry Zenone12, Nathalie Costedoat-Chalumeau7, Florian Perez13, Maxime Samson14, Anne-Marie Piette3, Guillaume Moulis10, Sylvain Audia15, Séverine Genot16, Nicolas Schleinitz17, Guillaume Lefevre5, Laurence Verneuil18, Olivier Benveniste19, Yves Allenbach1 and Boris Bienvenu20, 1Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, 2Internal Medicine, Caen University Hospital, Caen, France, 3Internal Medicine, Foch Hospital, Suresnes, France, 4Internal Medicine, Nantes University Hospital, Nantes, France, 5Internal Medicine, Lille University Hospital, Lille, France, 6Bichat University Hospital - Internal Medicine, Paris, France, 7Internal Medicine, Cochin University Hospital, Paris, France, 8Rheumatology, Strasbourg University Hospital, Strasbourg, France, 9Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, 10Internal Medicine, Toulouse University Hospital, Toulouse, France, 11Neurology, La Timone University Hospital, Marseille, France, 12Internal Medicine, Valence Hospital, Valence, France, 13Neurology, Albi Hospital, Albi, France, 14Dijon University Hospital, Dijon, France, 15Internal Medicine, Dijon University Hospital, Dijon, France, 16Internal Medicine, Martigues Hospital, Martigues, France, 17La Timone University Hospital, Marseille, France, 18Dermatology, Caen University Hospital, Caen, France, 19Pitié-Salpêtrière University Hospital, Paris, France, 20Caen University Hospital, Caen, France

    Background/Purpose:  Anti-Mi2 autoantibodies (Aabs) have been proposed to be highly specific for dermatomyositis (DM) and to be associated with a DM classical phenotype consisting of…
  • Abstract Number: 2320 • 2016 ACR/ARHP Annual Meeting

    Oropharyngeal Dysphagia in Autoimmune Myositis

    Jessica Nehme1, Jean-Paul Makhzoum2, Josiane Bourré-Tessier3, Yves Troyanov4, Marianne Landry1, Océane Landon-Cardinal5, Marvin J. Fritzler6, Anne-Marie Mansour7, Eric Rich8, Jean-Richard Goulet9, Tamara Grodzicky10, Edith Villeneuve2, Frédéric Massicotte11, Florence Weber12, Martial Koenig13, Sylvie Desmarais14, José Ferreira2, Benjamin Ellezam15, Ira N. Targoff16 and Jean-Luc Senécal2, 1Université de Montréal, Montreal, QC, Canada, 2Université de Montréal, Montréal, QC, Canada, 3Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 4Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, 5Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, 6Medicine, University of Calgary, Calgary, AB, Canada, 7medicine, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, 8Div of Rheumatology, C H Univ de Montreal, Montreal, QC, Canada, 9246 av Edison, CHUM - H, Saint-Lambert, QC, Canada, 10Rheumatology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, 11Hôpital Notre-Dame, Montr, QC, Canada, 12Hôpital St-Luc, Montreal, QC, Canada, 13Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, 14Centre Hospitalier Pierre-Boucher, Longueuil, QC, Canada, 15Hôpital Ste-Justine, Montreal, QC, Canada, 16University of Oklahoma, Oklahoma City, OK

    Background/Purpose:  Oropharyngeal dysphagia (OPD) is an ominous finding in autoimmune myositis (AIM), yet few studies have evaluated the disease subsets at higher risk for this…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology